Current and future treatment of metabolic syndrome and type 2 diabetes in children and adolescents

Diabetes Spectrum

Volumn 18, Issue 4, 2005, Pages 220-228

  Mallare, Johanna T ^a   Karabell, Ana H ^b   Velasquez Mieyer, Pedro ^c,d   Stander, Sarah R S ^e   Christensen, Michael L ^f  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c CDC   (United States)

^d Division of Endocrinology and Metabolism ^*

^e Department of Pediatrics and Adolescent Medicine

^f Department of Pediatrics ^*

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEPRAMONE; ANTILIPEMIC AGENT; CANNABINOID RECEPTOR ANTAGONIST; CHLORPHENTERMINE; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; CREATINE KINASE; FENOFIBRATE; FISH OIL; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER ENZYME; METFORMIN; MEVINOLIN; NICOTINIC ACID; OCTREOTIDE; OMEGA 3 FATTY ACID; PHENTERMINE; PHENYLPROPANOLAMINE; PRAVASTATIN; RIMONABANT; SIBUTRAMINE; SIMVASTATIN; STATINE DERIVATIVE; TETRAHYDROLIPSTATIN; TOPIRAMATE; UNINDEXED DRUG; VILDAGLIPTIN;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADOLESCENT; AGGRESSION; ANGIONEUROTIC EDEMA; ANOREXIA; APPETITE DISORDER; ARTHRALGIA; ASTHENIA; BARIATRIC SURGERY; BLOATING; BLOOD TOXICITY; BODY WEIGHT DISORDER; CHILD; CHOLELITHIASIS; CLINICAL TRIAL; COMORBIDITY; COST; COUGHING; CYANOCOBALAMIN DEFICIENCY; DEFECATION DISORDER; DIABETES MELLITUS; DIAPHORESIS; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DYSLIPIDEMIA; EUPHORIA; EYE IRRITATION; FATIGUE; FLATULENCE; GALLSTONE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEADACHE; HEART ARRHYTHMIA; HEART DISEASE; HEART PALPITATION; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERKALEMIA; HYPERTENSION; HYPOGLYCEMIA; HYPOTENSION; HYPOTHYROIDISM; INJECTION PAIN; INJECTION SITE REACTION; INSOMNIA; LACTIC ACIDOSIS; LIFESTYLE; LIVER TOXICITY; MEMORY DISORDER; MENTAL CONCENTRATION; METABOLIC SYNDROME X; MUSCLE WEAKNESS; NERVOUSNESS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PERIPHERAL EDEMA; PREVALENCE; PRURITUS; RESTLESSNESS; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; SKIN TOXICITY; SOMNOLENCE; STEATORRHEA; TREATMENT INDICATION; VISUAL IMPAIRMENT; VOMITING; XEROSTOMIA;

EID: 27844456867     PISSN: 10409165     EISSN: None     Source Type: Journal    
DOI: 10.2337/diaspect.18.4.220     Document Type: Review

References (75)

1. Steinberger J: Diagnosis of the metabolic syndrome in children. Curr Opin Lipidol 14:555-559, 2003
2. Daniels SR, Arnett DK, Eckel RH, Gidding SS, Hayman LL, Kumanyika S, Robinson TN, Scott BJ, Jeor SS, Williams CL: Overweight in children and adolescents: pathophysiology, consequences, prevention and treatment. Circulation 111:1999-2012, 2005
3. Cook S, Weitzman M, Auinger P, Nguen M, Dietz WH: Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch Pediatr Adolesc Med 157:821-827, 2003
4. Himes JH, Dietz WH: Guidelines for overweight in adolescent preventive services: recommendations from an expert committee. Am J Clin Nut 59:307-316, 1994
5. American Academy of Pediatrics: prevention of pediatric overweight and obesity (Policy Statement). Pediatrics 112:424-430, 2003
6. Yanovski JA, Yanovski SZ: Treatment of pediatric and adolescent obesity. JAMA 289:1851-1853, 2003
7. Daniels S: Pharmacological treatment of obesity in pediatric patients. Pediatr Drugs 3:405-410, 2001
8. Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J: Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 293:2873-2883, 2005
9. Berkowitz RI, Wadden TA, Tershakovec AM, Cronquist JL: Behavioral therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA 289:1805-1812, 2003
10. Kreymann B, Ghatei MA, Burnet P, Williams G, Kanse S, Diani AR, Bloo SR: Characterization of glucagon-like peptide-1-(7-36)amide in the hypothalamus. Brain Res 502:325-331, 1989
11. Freemark M, Bursey D: The Effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 107:E55, 2001
12. Kay JP, Alemzadeh R, Langley G, D'Angelo L, Smith P, Holshouser S: Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 50:1457-1461, 2001
13. Rauh JL, Lipp R: Chlorphentermine as an anorexigenic agent in adolescent obesity: report of its efficacy in a double-blind study of 30 teenagers. Clin Pediatr 7:138-140, 1968
14. Bray G, Greenway F: Current and potential drugs for treatment of obesity. Endocrine Rev 20:805-875, 1999
15. Lunetta M, Di Mauro M, Le Moli R, Burafato S: Long-term octreotide treatment reduced hyperinsulinemia, excess body weight and skin lesions in severe obesity with acanthosis nigricans. J Endocrinol Invest 19:699-703, 1996
16. Velasquez-Mieyer PA, Cowan PA, Arheart KL, Buffington CK, Spencer KA, Connelly BE, Cowan GW, Lustig RH: Suppression of insulin secretion is associated with weight loss and altered macronutrient intake and preference in a subset of obese adults. Int J Obesity Relat Metab Disord 27:219-226, 2003
17. Ormrod D, McClellan K: Topiramate: a review of its use in childhood epilepsy. Pediatr Drug 3:293-319, 2001
18. Levisohn P: Safety and tolerability of topiramate in children. J Child Neurol 15:S22-S26, 2000
19. Astrup A, Toubro S: Topiramate: a new potential pharmacological treatment for obesity. Obes Res 12 (Suppl.):167S-173S, 2000
20. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S, the RIO-Europe Study Group: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365:1389-1397, 2005
21. Mun EC, Blackburn GL, Matthews JB: Current status of medical and surgical therapy for obesity. Gastroenterology 120:669-681, 2001
22. Murr MM, Balsiger BM, Kennedy FP, Mail JL, Sarr MG: Malabsortive procedures for severe obesity: comparison of pancreaticobiliary bypass and very long limb roux-en-y gastric bypass. J Gastrointest Surg 3:607-612, 1999
23. Vandeplas Y, Bollen P, De Langhe K, Vandemaele K, De Schepper J: Intragastric balloons in adolescents with morbid obesity. Eur J Gastroenterol Hepatol 11:243-245, 1999
24. Howard L, Malone M, Michalek A, Carter J, Alger S, Van Woert J: Gastric bypass and vertical banded gastroplasty: a prospective randomized comparison and 5-year follow-up. Obesity Surg 5:55-60, 1995
25. Jones KB Jr: Experience with roux-en-y gastric bypass and commentary in current trends. Obes Surg 10:183-185, 2000
26. Doldi SB, Micheletto G, Lattuada E, Zappa MA, Bona D, Sonvico U: Adjustable gastric banding; 5-year experience. Obes Surg 10:171-173, 2000
27. Sugerman HJ, Sugerman EL, DeMaria EJ, Kellum JM, Kennedy C, Mowery Y, Wolfe LG: Bariatric surgery for severely obese adolescents. J Gastroint Surg 7:102-107, 2003
28. Dolan K, Creighton L, Hopkins G, Fielding G: Laparoscopic gastric banding in morbidly obese adolescents. Obesity Surg 13:101-104, 2003
29. Strauss R: Perspectives on childhood obesity. Curr Gastroenterol Rep 4:244-250, 2002
30. Kohen-Avramoglu R, Theriault A, Adeli K: Emergence of the metabolic syndrome in childhood: an epidemiological overview and mechanistic link to dyslipidemia. Clin Biochem 36:413-420, 2003
31. National Heart Foundation of Australia and the Cardiac Society of Austarlia and New Zealand: Lipid management guidelines-2001. Med J Aust 175 (Suppl. 5):S57-S88, 2001
32. Katzmarzyk PT, Perusse L, Malina RM, Bergeron J, Despres JP, Bouchard C: Stability of indicators of the metabolic syndrome from childhood and adolescence to young adulthood: the Quebec Family Study. J Clin Epidemiol 54:190-195, 2001
33. American Academy of Pediatrics, Committee on Nutrition: Cholesterol in childhood. Pediatrics 101:141-147, 1998
34. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (ATP III). JAMA 285:2486-2497, 2001
35. Kavey REW, Daniels SR, Lauer RM, Atkins DL, Haymann LL, Tauebert K: American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. Circulation 107:1562-1566, 2003
36. Writing Group for the DISC Collaborative Research Group: Efficacy and safety of lowering dietary intake of fat and cholesterol in children with elevated low-density lipoprotein cholesterol. JAMA 273:1429-1435, 1995
37. Jacobson MS, Tomopoulos S, Williams CL, Arden MR, Deckelbaum RJ, Starc TJ: Normal growth in high-risk hyperlipidemic children and adolescents with dietary intervention. Prev Med 27:775-780, 1998
38. Tonstad S, Knudtzon J, Sivertsen M, Refsum H, Ose L: Efficacy and safety of cholestyramine treatment in peripubertal and prepubertal children with familial hypercholesterolemia. J Pediatr 129:42-49, 1996
39. Simons LA, Sullivan DR: Lipid modifying drugs. Med J Aust 182:286-289, 2005
40. Hedman M, Matikainen T, Fohr A, Lappi M, Piippo S, Nuutinen M, Antikainen M: Efficacy and safety of pravastatin in children and adolescents with heterozygous familial hypercholesterolemia: a prospective clinical follow-up study. J Clin Endocrinol Metab 90:1942-1952, 2005
41. Stein EA, Illingworth DR, Kwiterovich PO Jr, Liacouras CA, Siimes MA, Jacobson MS, Brewster TG, Hopkins P, Davidson M, Graham K, Arensman F, Knopp RH, DuJovne C, Williams CL, Isaacsohn JL, Jacobsen CA, Laskarzewski PM, Ames S, Gormley GJ: Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. JAMA 281:137-144, 1999
42. Wiegman A, Hutten BA, de Groot E, Rodenburg J, Bakker HD, Buller HR, Sijbrands EJ, Kastelein JJ: Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 292:331-337, 2004
43. Li S, Chen W, Srinivasan SR, Bond MG, Tang R, Urbina EM, Berenson GS: Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study. JAMA 290:2271-2276, 2003
44. Rodenburg J, Vissers MN, Wiegman A, Trip MD, Bakker HD, Kastelein JJP: Familial hypercholesterolemia in children. Curr Opin Lipidol 15:405-411, 2004
45. de Jongh S, Lilien MR, op't Roodt J, Stroes ES, Bakker HD, Kastelein JJ: Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol 40:2117-2121, 2002
46. de Jongh S, Vissers MN, Rol P, Bakker HD, Kastelein JJ, Stroes ES: Plant sterols lower LDL cholesterol without improving endothelial function in prepubertal children with familial hypercholesterolaemia. J Inherit Metab Dis 26:343-351, 2003
47. Gagne C, Gaudet D, Bruckert E: Ezetimibe study group: efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 105:2469-2475, 2002
48. Pearson TA, Denke MA, Mc Bride PE, Battisti WP, Brady WE, Palmisano J: A community based, randomized trial of ezetimibe added-on to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the Ezetimibe Add-on to Statin For Effectiveness (EASE) Trial. Mayo Clinic Proc 80:587-595, 2005
49. Forrester JS, Makkar R, Shah PK: Increasing HDL cholesterol in dyslipidemia by cholesteryl ester transfer protein inhibition: an update for clinicians. Circulation 111:1847-1854, 2005
50. Steinmetz KL, Schonder KS: Colesevelam: potential uses for the newest bile resin. Cardiovasc Drug Rev 23:15-30, 2005
51. Izzo JLJ, Levy D, Black HR: Importance of systolic blood pressure in older Americans. Hypertension 35:1021-1024, 2000
52. Rocchini AP, Katch V, Anderson J, Hinderliter J, Becque D, Martin M, Marks C: Blood pressure in obese adolescents: effect of weight loss. Pediatrics 82:16-23, 1988
53. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents: The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114:555-576, 2004
54. Whitworth JA: Emerging drugs in the management of hypertension. Expert Opin Emerg Drug 8:377-388, 2003
55. Nakov R, Pfarr E, Eberle S: Darusentam an effective endothelin A receptor antagonist for treatment of hypertension. Am J Hypertens 15:583-589, 2002
56. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP: Aliskiren, a novel orally effective renin inhibitor, provide dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 111:1012-1018, 2005
57. Asmar R, Fredebohm W, Senftleber I, Chang PI, Gressin V, Saini RK: Omapatrilat compared with lisinopril in treatment of hypertension as assessed by ambulatory blood pressure monitoring. Am J Hypertens 13:143A, 2000
58. Zuhir-Yafi MI, Brosnan PG, Hardin DS: Treatment of T2DM mellitus in children and adolescents. J Pediatr Endocrinol Metab 15 (Suppl. 1):541-546, 2002
59. American Diabetes Association: Insulin administration (Position Statement). Diabetes Care 27:5106-5109, 2004
60. Prendergast BD: Glyburide and glipizide, second-generation oral sulfonylurea hypoglycemic agents. Clin Pharm 3:473-485, 1984
61. Skillman TG, Feldman JM: The pharmacology of sulfonylureas. Am J Med 70:361-372, 1981
62. Fuhlendorff J, Rorsman P, Kofod H, Brand CL, Rolin B, MacKay P Shymko R, Carr RD: Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct pathways. Diabetes 47:345-351, 1998
63. Bailey CJ, Path MRC, Turner RC: Metformin. N Engl J Med 334:574-579, 1996
64. U.K. Prospective Diabetes Study Group: Effect of intensive blood-glucose control with metformin on complications in over-weight patient with T2DM (UKPDS 34). Lancet 352:854-865, 1998
65. Jones KL, Arslanian S, Peterokova VA, Park JS, Tomlinson MJ: Effect of metformin in pediatric patients with T2DM: a randomized controlled trial. Diabetes Care 25:89-94, 2002
66. O'Moore-Sullivan TM, Prins JB: Thiazolidinediones and T2DM: new drugs for and old disease. Med J Aust 176:381-386, 2002
67. Egan J, Rubin C, Mathisen A, Pioglitazone 027 Study Group: Combination therapy with pioglitazone and metformin in patients with T2DM (Abstract). Diabetes 48:A117, 1999
68. Egan J, Rubin C, Mathisen A, Pioglitazone 027 Study Group: Adding pioglitazone to metformin therapy improves the lipid profile in patients with T2DM. Diabetes 48:A106, 1999
69. Salvatore T, Giugliano D: Pharmacokinetic-pharmacodynamic relationships of acarbose. Clin Pharmacokinet 30:94-106, 1996
70. Clissold SP, Edwards C: Acarbose: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 35:214-243, 1988
71. Eldelman SV: Practice approach to combination therapy: daytime oral agent(s) and bedtime NPH insulin. Clin Diabetes 3:100-110, 1999
72. Uwaifo GI, Ratner RE: Novel pharmacologic agents for type 2 diabetes. Endocrinol Metab Clin N Am 34:155-197, 2005
73. Pramlintide (Symlin) for diabetes. Med Letter 47:43-44, 2005
74. Nauck MA, Meier JJ: Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Regul Pept 128:135-148, 2005
75. Guerre-Millo M, Gervois P, Raspe E, Madsen L, Poulain P, Derudas B, Herbert JM, Winegar DA, Wilson TM, Fruchart JC, Berge RK, Staels B: Peroxisome proliferators-activated receptor α activators improve insulin sensitivity and reduce adiposity. J Biol Chem 275:16638-16642, 2000